Natural killers gain more attention with major Franco-US collab

27 September 2022
gene_genetic_test_biotech_biomarker_lab_research_2022_big

Californian genetic medicine company Scribe Therapeutics has scored a major strategic collaboration with French giant Sanofi (Euronext: SAN).

The molecular engineering company, which is working on what it calls a “CRISPR by Design” platform for genetic medicine, is offering its gene editing capabilities for use in the creation of novel natural killer (NK) cell therapies for cancer.

As well as $25 million right away, Scribe will be eligible for in excess of $1 billion in payments based on development and commercial milestones, plus royalties on sales.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology